Assessing health-related quality of life in patients with benign non-toxic goitre

Torquil Watt*, Per Cramon, Daniel M. Frendl, John E. Ware

*Corresponding author for this work

Research output: Contribution to journalReviewResearchpeer-review

18 Citations (Scopus)

Abstract

Health-related quality of life (HRQoL) assessments are increasingly used to evaluate treatment effects and to shape the delivery of value based care. Valid generic and disease specific tools are available for quantifying HRQoL in patients with non-toxic goitre. However, few studies have applied these validated instruments to assess HRQoL in patients with benign non-toxic goitre. Limited evidence suggests that patients with non-toxic goitre have HRQoL impairments in multiple HRQoL domains. While the HRQoL-impact of non-toxic goitre may be small relative to other severely disabling medical conditions, treatment is almost exclusively elected for HRQoL indications. Thus better quantification of HRQoL, particularly at better (or more favorable) levels where many patients score, is essential. Web and mobile technologies have eased the ability to deliver surveys to patients. Routine consideration of HRQoL provides the opportunity to monitor the impact of treatment on the outcomes most meaningful for patients and the opportunity to help shape the delivery of value based health care.

Original languageEnglish
JournalBest Practice and Research: Clinical Endocrinology and Metabolism
Volume28
Issue number4
Pages (from-to)559-575
Number of pages17
ISSN1521-690X
DOIs
Publication statusPublished - Aug 2014

Keywords

  • non-toxic goitre
  • patient-reported outcome measure
  • quality of life

Cite this